Core Viewpoint - A securities class action lawsuit has been filed against Zynex, Inc. for allegedly misleading investors regarding its revenue practices and product shipments [1][3]. Company Overview - Zynex, Inc. is a medical device company based in Englewood, CO, specializing in electrotherapy devices for pain management and rehabilitation [2]. Lawsuit Details - The lawsuit claims that Zynex shipped products, including electrodes, beyond actual demand, allowing the company to inflate its revenue [3]. - It is alleged that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, which could lead to adverse consequences such as removal from insurer networks and federal penalties [3]. Investor Information - Investors who purchased Zynex securities during the class period (March 13, 2023, to March 11, 2025) have until May 19, 2025, to seek appointment as lead plaintiff [2].

Core Viewpoint - A class-action lawsuit has been filed against Zynex, Inc. alleging that the company misled investors by inflating revenue through excessive and unnecessary shipments of medical supplies to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit, Tuncel v. Zynex, Inc., seeks to represent individuals and entities who purchased Zynex securities between March 13, 2023, and March 11, 2025, with a lead plaintiff deadline of May 19, 2025 [2][3]. - The complaint alleges that Zynex engaged in a scheme to inflate reported revenue by sending more products than medically necessary, which drew scrutiny from insurers like Tricare [3][4]. - Following a report in the medical journal STAT detailing Zynex's alleged oversupplying scheme, the company's stock price fell by over 5% [4]. Group 2: Financial Impact - Zynex disclosed a significant revenue shortfall for Q4 2024, attributing it to slower payments from certain payers, including a temporary suspension of payments from Tricare [5]. - The announcement of the revenue shortfall led to a sharp decline in Zynex's share price, which plummeted by more than 51% [5]. - In Q1 2025, Zynex reported net revenue of $26.6 million, down from $46.5 million in the same period of 2024, with a gross profit margin contracting to 69% from 80% [6]. Group 3: Future Outlook - Zynex has issued a muted revenue guidance of $27 million for Q2 2025 and anticipates an earnings per share (EPS) loss of $0.20, withholding full-year financial guidance due to uncertainty with Tricare [8]. - The CEO of Zynex acknowledged the impact of the Tricare payment suspension on revenue and indicated that the company is initiating a restructuring effort [7].

PHILADELPHIA, April 24, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ: ZYXI) on behalf of purchasers of Zynex securities between March 13, 2023 through March 11, 2025, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired Zynex securities during the Class Period may, no later than MAY 19, 2025, seek to be appointed as a lead plaintiff representative of the ...